Literature DB >> 15014062

Analysis of AmpC beta-lactamase expression and sequence in biochemically atypical ceftazidime-resistant Enterobacteriaceae from paediatric patients.

Matthew B Avison1, Sarah Underwood, Aki Okazaki, Timothy R Walsh, Peter M Bennett.   

Abstract

OBJECTIVES: To analyse the variation of ampC beta-lactamase gene sequence and expression in biochemically atypical Enterobacteriaceae isolates, and to identify them definitively.
METHODS: beta-Lactamase gene-containing recombinant plasmids transformed into Escherichia coli were selected using ampicillin. PCR analysis was used to locate specific ampC and 16S rRNA genes, and the amplicons were sequenced. Random amplified polymorphic DNA PCR was used to group isolates and API 20E biochemical profiling was used to identify them putatively.
RESULTS: Of 50 ceftazidime-resistant clinical Enterobacteriaceae isolates, 36 were identified (>95% confidence)-using API 20E test strips-as being organisms known to express inducible class C beta-lactamases (Citrobacter freundii, Enterobacter cloacae, Morganella morganii or Hafnia alvei). The rest were biochemically atypical. Of these, isolate I113, putatively identified as E. coli, possesses a chromosomally encoded ampC which differs by 15% from C. freundii OS60 ampC and by >30% from E. coli ampC. A related ampC gene was found in another seven of the atypical isolates. The use of various identification methods, including ampC sequence analysis, revealed that these I113-like ampC-positive isolates represent Citrobacter murliniae and Citrobacter youngae.
CONCLUSIONS: We report sequences for two new Citrobacter spp. ampC genes, and provide evidence that ampC sequencing is a discriminatory method for identifying atypical Citrobacter spp. isolates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15014062     DOI: 10.1093/jac/dkh151

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Evidence of antibiotic resistance gene silencing in Escherichia coli.

Authors:  Virve I Enne; Anne A Delsol; John M Roe; Peter M Bennett
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.

Authors:  Thierry Naas; Daniel Aubert; Ayla Ozcan; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

3.  Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.

Authors:  Karina Calvopiña; Klaus-Daniel Umland; Anna M Rydzik; Philip Hinchliffe; Jürgen Brem; James Spencer; Christopher J Schofield; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 4.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

5.  Involvement of mutation in ampD I, mrcA, and at least one additional gene in β-lactamase hyperproduction in Stenotrophomonas maltophilia.

Authors:  Asmaa Talfan; Oliver Mounsey; Matthew Charman; Eleanor Townsend; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

Review 6.  The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases.

Authors:  Sadeeq Ur Rahman; Tariq Ali; Ijaz Ali; Nazir Ahmad Khan; Bo Han; Jian Gao
Journal:  Biomed Res Int       Date:  2018-03-26       Impact factor: 3.411

7.  Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders.

Authors:  Elena Biagi; Daniele Zama; Simone Rampelli; Silvia Turroni; Patrizia Brigidi; Clarissa Consolandi; Marco Severgnini; Eleonora Picotti; Pietro Gasperini; Pietro Merli; Nunzia Decembrino; Marco Zecca; Simone Cesaro; Maura Faraci; Arcangelo Prete; Franco Locatelli; Andrea Pession; Marco Candela; Riccardo Masetti
Journal:  BMC Med Genomics       Date:  2019-03-07       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.